Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy

被引:6
作者
Janes, RJ [1 ]
Muhonen, T
Karjalainen, UP
Wiklund, T
机构
[1] Univ Helsinki Hosp, Dept Oncol, Helsinki 00290, Finland
[2] Univ Helsinki Hosp, Dept Clin Chem, Helsinki 00290, Finland
关键词
emesis; nausea; vomiting; 5-HIAA; serotonin; type-3 serotonin antagonists; chemotherapy;
D O I
10.1016/S0959-8049(97)00322-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Highly emetogenic drugs such as cisplatin induce an increase in the urinary 5-hydroxyindoleacetic acid (5-HIAA) level, the main metabolite of serotonin (5-HT), within the first 24 h following a single infusion, thus providing a possible cause for acute emesis and an explanation for the action of 5-HT3 antagonists. No further excretion peaks have been observed, suggesting that additional or serotonin-independent mechanisms cause delayed emesis. Our aim was to study the mechanisms behind emesis seen during a highly emetogenic chemotherapy regimen given as a continuous infusion over several days. Seven women treated with a I-day high-dose chemotherapy (HDCT) regimen for breast cancer entered the study. Pooled urine samples were collected prior to and during chemotherapy for determining 5-HIAA excretion. An excretion peak in the urinary 5-HIAA level was observed within the first 24 h with no further peaks thereafter. Thus, the mechanisms behind the emesis experienced during this highly emetogenic multiple-day chemotherapy regimen from days 2-3 onwards would appear to be at least partially serotonin independent and would not be expected to be completely relieved by 5-HT3 antagonists alone. (C) 1998 Elsevier Science Ltd.
引用
收藏
页码:196 / 198
页数:3
相关论文
共 47 条
  • [31] SERUM 5'-NUCLEOTIDASE AND ALKALINE-PHOSPHATASE ACTIVITIES AFTER HIGH-DOSE CHEMOTHERAPY AND BONE-MARROW TRANSPLANTATION IN CASES OF MALIGNANCY IN CHILDREN
    CLERCRENAUD, P
    SOUILLET, G
    LAHET, C
    SOTTA, C
    MATHIEU, M
    MOUSSON, B
    ANNALES DE BIOLOGIE CLINIQUE, 1995, 53 (03) : 125 - 130
  • [32] BIWEEKLY 2-DAY SCHEDULE OF HIGH-DOSE FOLINIC ACID, 5-FLUOROURACIL BOLUS AND INFUSION IN PRETREATED ADVANCED EPITHELIAL OVARIAN-CANCER - A PHASE-II STUDY
    LOUVET, C
    DEGRAMONT, A
    DEMUYNCK, B
    VARETTE, C
    BEERBLOCK, K
    BENNAMOUN, M
    KRULIK, M
    ANNALS OF ONCOLOGY, 1992, 3 (08) : 657 - 658
  • [33] HIGH-DOSE 5-FLUOROURACIL AND LEUCOVORIN AS 2ND-LINE CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN-CANCER
    KAMPHUIS, JT
    HUIDER, MC
    RAS, GJ
    VERHAGEN, CAH
    KATEMAN, I
    VREESWIJK, JHA
    BURGHOUTS, JTM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 37 (1-2) : 190 - 192
  • [34] Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens
    Moehler, M
    Hoffmann, T
    Hildner, K
    Siebler, J
    Galle, PR
    Heike, M
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2002, 40 (12): : 957 - 964
  • [35] Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma
    Kallen, KJ
    Hofmann, MAK
    Timm, A
    Godderz, W
    Galle, PR
    Heike, M
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2000, 38 (02): : 153 - 157
  • [36] Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study
    Janinis, J
    Papakostas, P
    Samelis, G
    Skarlos, D
    Papagianopoulos, P
    Fountzilas, G
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 163 - 167
  • [37] CD4+ CD28+ lymphocytes on day 5 after high-dose melphalan for multiple myeloma predict a low risk of infections during severe neutropenia and are associated with the number of reinfused T lymphocytes of the autologous stem cell graft
    Schmidmaier, Ralf
    Then, Cornelia
    Schnabel, Brigitte
    Oduncu, Fuat
    Baumann, Philipp
    Straka, Christian
    CYTOTHERAPY, 2011, 13 (08) : 987 - 992
  • [38] HIGH-DOSE FOLINIC ACID, 5-FLUOROURACIL BOLUS AND CONTINUOUS INFUSION IN POOR-PROGNOSIS PATIENTS WITH ADVANCED MEASURABLE GASTRIC-CANCER
    LOUVET, C
    DEGRAMONT, A
    DEMUYNCK, B
    NORDLINGER, B
    MAISANI, JE
    LAGADEC, B
    DELFAU, S
    VARETTE, C
    GONZALEZCANALI, G
    KRULIK, M
    ANNALS OF ONCOLOGY, 1991, 2 (03) : 229 - 230
  • [39] SEQUENTIAL COMBINATION OF METHOTREXATE (MTX), 5-FLUOROURACIL (FU), AND HIGH-DOSE FOLINIC ACID (FA) IN ADVANCED COLORECTAL-CANCER - DOUBLE BIOCHEMICAL MODULATION
    ABAD, A
    ROSELL, R
    PASTOR, MC
    BARNADAS, A
    CARLES, J
    RIBELLES, N
    OLLER, B
    ARMENGOL, M
    SALVA, A
    RIBAS, M
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (05): : 393 - 396
  • [40] Phase II study of weekly high-dose 5-fluorouracil and folinic acid plus biweekly alternating cisplatin and epirubicin (FUFACE) in patients with advanced gastric carcinoma
    Stahl, M
    Vanhoefer, U
    Fink, U
    Korn, M
    Eigler, FW
    Siewert, JR
    Seeber, S
    Wilke, H
    ONKOLOGIE, 1996, 19 (05): : 416 - 418